Uso de sustancias psicoactivas como tratamiento de la psicosis
Revista de Neurología January 1, 2023 E Serrano-Jiménez, M G de Lucas-Moreno
A systematic review of 28 articles examined whether cannabidiol, modafinil, and ketamine offer benefits as adjunctive treatments for psychotic disorders. Cannabidiol improved positive symptoms and overall psychopathology; modafinil enhanced cognitive symptoms, motor and emotional functioning, and quality of life; and ketamine improved negative symptoms. All three substances showed good tolerability and safety profiles, especially compared to antipsychotics. The findings suggest these psychoactive substances could serve as adjunctive options for clinicians treating patients with psychotic conditions.